Terms: = Breast cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
7581 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
Han JY; Che N; Mo J; Zhang DF; Liang XH; Dong XY; Zhao XL; Sun BC
BMC Cancer; 2024 Apr; 24(1):532. PubMed ID: 38671389
[TBL] [Abstract] [Full Text] [Related]
3. Human Blood Serum Counteracts egfr/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression.
Shaban N; Raevskiy M; Zakharova G; Shipunova V; Deyev S; Suntsova M; Sorokin M; Buzdin A; Kamashev D
Biochemistry (Mosc); 2024 Mar; 89(3):487-506. PubMed ID: 38648768
[TBL] [Abstract] [Full Text] [Related]
4. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
5. Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach.
Alsaiari AA; Gharib AF; Bakhuraysah MM; Alrehaili AA; Algethami SM; Alsaif HA; Al Harthi N; Hakami MA
Med Oncol; 2024 Apr; 41(5):117. PubMed ID: 38630325
[TBL] [Abstract] [Full Text] [Related]
6. Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative breast cancer.
Fan T; Huang Y; Liu Z; Huang J; Ke B; Rong Y; Qiu H; Zhang B
Drug Des Devel Ther; 2024; 18():1115-1131. PubMed ID: 38618280
[TBL] [Abstract] [Full Text] [Related]
7. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
8. Single cell lineage tracing reveals clonal dynamics of anti-egfr therapy resistance in triple negative breast cancer.
Pellecchia S; Franchini M; Viscido G; Arnese R; Gambardella G
Genome Med; 2024 Apr; 16(1):55. PubMed ID: 38605363
[TBL] [Abstract] [Full Text] [Related]
9. Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents.
Kamboj P; Anjali ; Imtiyaz K; Rizvi MA; Nath V; Kumar V; Husain A; Amir M
Sci Rep; 2024 Apr; 14(1):8457. PubMed ID: 38605072
[TBL] [Abstract] [Full Text] [Related]
10. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the egfr pathway.
Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
[TBL] [Abstract] [Full Text] [Related]
11. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
[TBL] [Abstract] [Full Text] [Related]
12. Biocompatible and Water-Soluble Shortwave-Infrared (SWIR)-Emitting Cyanine-Based Fluorescent Probes for In Vivo Multiplexed Molecular Imaging.
Swamy MMM; Murai Y; Monde K; Tsuboi S; Swamy AK; Jin T
ACS Appl Mater Interfaces; 2024 Apr; 16(14):17253-17266. PubMed ID: 38557012
[TBL] [Abstract] [Full Text] [Related]
13. Molecular and functional insight into anti-egfr nanobody: Theranostic implications for malignancies.
Tripathy RK; Pande AH
Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
[TBL] [Abstract] [Full Text] [Related]
14. Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion.
Ye F; Yuan Z; Tang Y; Li J; Liu X; Sun X; Chen S; Ye X; Zeng Z; Zhang XK; Zhou H
Cell Rep; 2024 Apr; 43(4):114002. PubMed ID: 38547126
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Values of CD8+, PARP, and egfr on Overall Survival in Patients with Triple-Negative breast cancer.
Putri RI; Haryono SJ; Brahma B; Prayitno YH; Sutandyo N
Asian Pac J Cancer Prev; 2024 Mar; 25(3):1025-1034. PubMed ID: 38546085
[TBL] [Abstract] [Full Text] [Related]
16. Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies.
Camorani S; Caliendo A; Morrone E; Agnello L; Martini M; Cantile M; Cerrone M; Zannetti A; La Deda M; Fedele M; Ricciardi L; Cerchia L
J Exp Clin Cancer Res; 2024 Mar; 43(1):92. PubMed ID: 38532439
[TBL] [Abstract] [Full Text] [Related]
17. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells.
Kar T; Dugam P; Shivhare S; Shetty SR; Choudhury S; Sen D; Deb B; Majumdar S; Debnath S; Das A
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2049. PubMed ID: 38522013
[TBL] [Abstract] [Full Text] [Related]
19. Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography.
Ma Z; Xu J; Hou W; Lei Z; Li T; Shen W; Yu H; Liu C; Zhang J; Tang S
Anal Chem; 2024 Apr; 96(13):5195-5204. PubMed ID: 38520334
[TBL] [Abstract] [Full Text] [Related]
20. Clinical, Epidemiologic, and Pathologic Significance of erbb2-Low Expression in breast cancer.
Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
[TBL] [Abstract] [Full Text] [Related]
[Next]
